A Phase I, Open-Label, Single Institution Study to Assess the Safety, Tolerability, and Pharmacokinetics of Durvalumab in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, and Central Nervous System Tumors
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Durvalumab (Primary)
- Indications Adrenocortical carcinoma; Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Hepatoblastoma; Lymphoma; Nervous system neoplasms; Osteosarcoma; Rhabdomyosarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; Pharmacokinetics
- 20 Sep 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Planned End Date changed from 1 Dec 2020 to 1 Jun 2023.
- 19 Apr 2023 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2023.